Evaluation of the relationship between ABCG2 mutation and teriflunomide exposure and safety in Chinese RMS patients treated with teriflunomide 14 mg once daily for 24 weeks

Trial Identifier: BDR16019
Sponsor: Sanofi
Start Date: May 2020
Primary Completion Date: July 2021
Study Completion Date: July 2021
Condition: Multiple Sclerosis (MS)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
China China, China